36% to 50% of patients progress to end-stage renal disease within 10 years.[1] The fluorescence intensity of C3 in pathology is inversely proportional to the prognosis of C3G.[3] Generally speaking, the prognosis of C3GN is better than that of DDD. The gene discussed is C3; the disease is complement 3 glomerulopathy.